Islet Allotransplantation With Steroid Free Immunosuppression
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
The restoration of endogenous insulin secretion carries significant hopes for shifting the
paradigm of life long exogenous insulin therapy in selected groups of patients with type 1
diabetes(T1D). After decades of frustrating clinical attempts, the Edmonton group set up in
2000 new standards for islet transplantation in patients with brittle T1D by achieving
insulin independence in 80 percent of patients. These seminal results have however proved
much more difficult to duplicate than initially expected.
This single center phase 2 clinical trial, duplicating the Edmonton protocol, is designed for
confirming the consistent short term efficacy and safety of sequential islet
allotransplantation with steroid free immunosuppression in patients with severe T1D.